www.tagesschau.de
Präsident Lula tritt zur Wiederwahl an
Der 80-Jährige wurde von seiner Partei erneut nominiert. Sein wichtigster Konkurrent steht bereits fest.
#LulaDaSilva is an active hashtag on Bluesky. In the last 30 days, 22 people shared 68 posts with it — around 2 a day. Activity is up 18% versus the previous week, peaking on Aug 8 with 16 posts.
Tags most often used together with #LulaDaSilva.
www.tagesschau.de
"Brasilien ist der richtige Standort"
Brasiliens Präsident Lula wirbt im tagesthemen-Interview für deutsche Investitionen in seinem Land.
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
www.ipharmacenter.com
ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026
Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.